Safety and efficacy of aspirin and indobufen in the treatment of coronary heart disease: a systematic review and meta-analysis
Authors:
Open Access
- 15 August 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1412944
Abstract
Purpose: This meta-analysis aimed to compare the safety and efficacy of aspirin and indobufen in patients with coronary heart disease. The primary focus was on the incidence of cardiovascular events, bleeding events, and gastrointestinal reactions. Given the relatively limited research on indobufen, this study utilized aspirin as a control drug and employed meta-analysis to integrate existing clinical studies. The goal was to provide a reference for the clinical use of indobufen and to suggest directions for further largescale, multicenter prospective studies.Methods: This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We conducted a comprehensive search of the PubMed, EMBASE, WOS, and Cochrane Library databases to identify all relevant literature on indobufen. A total of nine trials met the inclusion criteria, encompassing seven randomized controlled trails (RCTs) and two retrospective studies. Categorical variables were analyzed using odds ratio and random effects models.Results: The meta-analysis included nine trials, comprising seven RCTs and two retrospective studies. The pooled results indicated that indobufen significantly reduced the incidence of minor bleeding events, and gastrointestinal discomfort compared to aspirin. However, both drugs had similar effects on the incidence of recurrent angina pectoris, myocardial infarction and mortality due to coronary heart disease.Conclusion: Indobufen was associated with fewer gastrointestinal reactions and a low risk of bleeding, making it a viable option for patients with high-risk factors for bleeding and gastric ulcers. Despite this, indobufen's short history and limited evidence base compared to aspirin highlight the need for further research. Aspirin remains widely available, cost-effective, and the preferred drug for the primary and secondary prevention of cardiovascular and cerebrovascular diseases. Indobufen or other antiplatelet agents should only be considered when aspirin is not tolerated or contraindicated. Further clinical trials are necessary to determine whether indobufen can replace aspirin.Systematic Review Registration: https://www.crd.york.ac.uk/, identifier [CRD42024523477].Keywords
This publication has 12 references indexed in Scilit:
- Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registryBMC Medicine, 2024
- Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point–Blinded, Noninferiority TrialCirculation, 2023
- Effect of indobufen vs. aspirin on platelet accumulation in patients with stable coronary heart disease after percutaneous coronary intervention: An open-label crossover studyFrontiers in Pharmacology, 2022
- Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosisEuropean Journal of Clinical Pharmacology, 2021
- Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of InterventionsCochrane Database of Systematic Reviews, 2019
- Platelet Activation and AtherothrombosisNew England Journal of Medicine, 2007
- Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgeryCoronary Artery Disease, 1998
- Indobufen Versus Warfarin in the Secondary Prevention of Major Vascular Events in Nonrheumatic Atrial FibrillationStroke, 1997
- Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass graftingThe Journal of Thoracic and Cardiovascular Surgery, 1994